Study results indicate that maintenance doses of bimekizumab (320 mg) every four or eight weeks can maintain high levels of skin clearance at two years in patients with moderate to severe plaque psoriasis. The data was presented during the summer meeting of the American Academy of Dermatology in Tampa, Fla., and summarized in this press release.
Bimekizumab is an investigational IL-17A and IL-17F inhibitor for moderate to severe plaque psoriasis and has not been approved for use in Canada or the United States.
This study was an open-label extension (OLE) of the Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE BRIGHT). Results showed that the majority of patients who achieved complete or near-complete skin clearance after 16 weeks of treatment with bimekizumab were able to maintain these responses through to two years with continuous maintenance dosing at 320 mg, at every four or eight weeks.
In addition to positive IGA and BSA assessments, of the 989 patients enrolled, more than eight out of 10 with complete skin clearance (PASI 100) at week 16 maintained their PASI response to week 48 in the OLE trial (80.7% and 86.1% with continuous maintenance dosing every four weeks and every eight weeks, respectively).
“These data are meaningful for the dermatology community and further add to the clinical evidence we have from the bimekizumab Phase 3 clinical program,” said Dr. Mark Lebwohl, Dean for Clinical Therapeutics, Icahn School of Medicine at Mount Sinai in New York, who presented the data at the Summer AAD session.